(Q42703601)

5 November 2017

Identification of potential drugs for Parkinson's disease based on a sub-pathway method (English)

1 reference

5 November 2017

1 reference

Ai-Guo Sun

1

1 reference

5 November 2017

Ai-Qi Lin

2

1 reference

5 November 2017

Shao-Yue Huang

3

1 reference

5 November 2017

Di Huo

4

1 reference

5 November 2017

Chao-Hua Cong

5

1 reference

5 November 2017

18 November 2014

1 reference

International Journal of Neuroscience

5 November 2017

1 reference

5 November 2017

126

1 reference

5 November 2017

4

1 reference

5 November 2017

318-325

1 reference

Genetic and environmental factors in the cause of Parkinson's disease

5 November 2017

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Genetic variants and animal models in SNCA and Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Genetics of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Environmental toxins and alpha-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Pharmacological treatment of Parkinson disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Parkinson's disease. Second of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

A genomic pathway approach to a complex disease: axon guidance and Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Characterizing the network of drugs and their affected metabolic subpathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Regulated formation of eicosanoids

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Chronic lithium chloride administration to unanesthetized rats attenuates brain dopamine D2-like receptor-initiated signaling via arachidonic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

D-Amphetamine stimulates D2 dopamine receptor-mediated brain signaling involving arachidonic acid in unanesthetized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Tyrosine hydroxylase and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Overview of tyrosine hydroxylase in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Activation of the proopiomelanocortin gene with ketoconazole as a treatment for Parkinson's disease: a new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

The role of autophagy in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

An overview of bilastine metabolism during preclinical investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

Le traitement par apomorphine en perfusion continue sous-cutanée dans la maladie de Parkinson : analyse rétrospective d’une série de 81 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2014.986673

10.3109/00207454.2014.986673

21 January 2018

Identifiers

DOI

1 reference

5 November 2017

1 reference